BIOMAT Database Logo BIOMAT Database Logo

A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer. 1982

D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn

A total of 156 patients with metastatic breast cancer were entered into a prospective multi-center trial in September 1975. All patients were treated monthly with vincristine, adriamycin and cyclophosphamide (VAC) six times, followed by 5-fluorouracil, methotrexate and cyclophosphamide (FMC) until progression was documented. By random assignment, the patients received 5 mg/m2 Corynebacterium parvum (CP) subcutaneously on day 1, in addition to VAC/FMC. Of the 150 evaluable patients, 33 of 76 (45%) and 36 of 74 (49%) had complete or partial response to VAC/FMC plus CP, respectively. The Kaplan-Maier curves of duration of remission and survival were almost identical (medians 14.5 vs 12.1 months and 22.2 vs 21.1 months, respectively). The hematologic and gastrointestinal toxicity were also similar in the two study groups. However, 19 of 74 (26%) patients developed skin ulcers after repeated injections of CP. These patients showed prolonged survival (P = 0.002, log rank test). These results suggest that adding nonspecific immunostimulation with CP to currently available chemotherapy on day 1 is of no benefit to most patients with metastatic breast cancer, but may select an "immunoreactive subgroup with increased local toxicity and survival.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011425 Propionibacterium acnes A bacteria isolated from normal skin, intestinal contents, wounds, blood, pus, and soft tissue abscesses. It is a common contaminant of clinical specimens, presumably from the skin of patients or attendants. Corynebacterium acnes,Corynebacterium parvum
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Randomized trial in advanced breast cancer using combination chemotherapy with or without C. parvum; preliminary results.
January 1977, Developments in biological standardization,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Corynebacterium parvum and metastatic breast cancer.
May 1982, British journal of cancer,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
[Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
February 1999, Harefuah,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
[Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
August 1982, Onkologie,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
January 2021, JAMA oncology,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
June 1982, Cancer treatment reports,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study.
December 1985, Journal of steroid biochemistry,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study.
January 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
December 2003, Oncology (Williston Park, N.Y.),
D Fritze, and R Becher, and B Massner, and M Kaufmann, and U Bruntsch, and W M Gallmeier, and A C Mayr, and P Drings, and U Abel, and L Edler, and W F Jungi, and W Queisser, and H J Senn
Combination chemotherapy in metastatic breast cancer.
July 1977, British medical journal,
Copied contents to your clipboard!